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Abstract: 
Background: The diagnosis of asthma can be challenging and is based on clinical 
symptoms, physical examination, and pulmonary function tests. Most patients with 
asthma will have a significant post-bronchodilator response on spirometry indicating 
airway hyper-responsiveness. However, having a significant bronchodilator response by 
itself is not diagnostic of asthma. Also, the definition of a "significant" response is 
controversial. Many respirologists use the American Thoracic Society (A TS) post-
bronchodilator response criteria of 12% (provided it is~ 200 ml) improvement in FEVI 
(or FCV) from the baseline spirometry. 
Methods: This study retrospectively reviewed 644 patients who met the A TS criteria for 
a significant post-bronchodilator spirometric response. The staffrespirologist's diagnosis 
of asthma, based on all clinical and pulmonary function data, was used as the standard for 
the diagnosis of asthma. 
Results: It was found that relying on spirometric criteria alone was inadequate in asthma 
diagnosis as only 54.7% of 310 patients meeting A TS bronchodilator response criteria 
were felt to have asthma clinically. Increasing the post-bronchodilator percent 
improvement from the A TS criteria only marginally improved diagnostic specificity and 
resulted in a decline in sensitivity. 
Conclusions: This further emphasizes the need to use spirometric criteria as a guide but 
not as an unimpeachable gold standard by which to make a diagnosis of asthma. The 
diagnosis of asthma depends on a combination of expert physician correlation of history, 
physical examination, and pulmonary function test results. 
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1.0 INTRODUCTION: 
1.1 Background: 
Asthma is an inflammatory disease of the airways with generally reversible airflow obstruction 
and airway hyper-responsiveness causing episodic respiratory symptoms [1]. An expanded disease 
definition is that it is characterized by wide variations over short periods of time in airflow resistance 
of the lung airways, and clinically by recurrent attacks of cough or wheeze separated by symptom free 
intervals. The airflow obstruction and clinical symptoms are largely or completely reversed by 
treatment with bronchodilator drugs and/or steroids [2]. While these are somewhat unwieldy 
definitions, it is important to have a clear understanding what exactly encompasses asthma. This is 
because asthma is likely not a specific disease but rather a syndrome that occurs from multiple 
precipitating mechanisms. These precipitating factors result in a common clinical complex involving a 
classical triad of reversible obstruction, inflammation of the airways, and airway hyperresponsiveness. 
In contrast, chronic obstructive pulmonary disease (COPD) is defined by the presence of airflow 
limitation that is not fully reversible after inhaled bronchodilators [3]. 
1.2 History of Asthma: 
Asthma type symptoms have been reported since ancient times. Hippocrates 
described asthma symptoms in children and related the prevalence of disease to the 
weather/wind, seasons of the year, and water supply [4]. Galen wrote about catarrh with 
rapid breathing and "a feeling of constriction" which likely represented asthma [5] . 
Asthma was first clearly described in the English language literature by Sir John Floyer 
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in 1698 [6]. He gave clear observations about acute asthma attacks and asthma in general. 
Numerous physicians and scientists furthered the understanding of asthma including 
Laennec as well as Henry Salter who, in the 1859, described the hereditary component of 
asthma [7]. William Osler taught his students the modern theory that asthma was a 
bronchial disease with obstructing mucus, mucosal edema, and bronchial wall muscular 
contraction [8]. In the twentieth century, there was a progressive improvement in the 
understanding of asthma pathophysiology, diagnostic criteria, and treatment methods. 
Two ofthe most significant advances included Tiffeneau's description of forced 
expiratory volume at one second (FEV 1) in 1949, as well as the discovery of synthetic 
cortisone by Kendall & Hench in 1948 with the subsequent use in asthma therapy by 
cortisone injection in 1950 and by beclomethasone inhalation in 1971 [9, 10, 11]. 
1.3 Epidemiology of Asthma: General Overview 
Asthma affects between 6-1 0% of the North American population and the 
prevalence has increased by nearly 75% over that last 20 years [12]. There are over 4000 
deaths every year in the United States from asthma while data from Canada is less well 
defined [13]. While the prevalence of asthma is clearly increasing over the last 20 years 
the reasons behind this increase remain elusive. Some of the theories raised include 
increasing industrialization with increased pollution, obesity, sedentary lifestyle with 
increased indoor exposure to allergens, improvements in asthma reporting rates, and 
other factors. In the United States, asthma prevalence increased 73.9% from 1980 to 1996 
with rates increasing from 3 1. 4 per 1 000 to 54.6 per 1 000 population [ 14]. 
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Asthma surveillance is at times challenging to determine in part due to the 
difficulties of accurate diagnosis. Surveys of asthma depend on the physician's diagnosis 
of asthma based on physical examination and the patient's report of symptoms as well as 
certain supplementary pulmonary function testing. Obviously, there may be issues with 
the accuracy of the physician's diagnosis, the patient's symptoms, and the pulmonary 
function testing. Thus, inaccuracies may be compounded and the actual prevalence of 
asthma over- or under-reported. In 1997, the U.S. National Center for Health Statistics 
changed the annual asthma questionnaire form to improve the measurement of asthma 
prevalence. Since that time, the data collected shows a stabilization in asthma prevalence 
compared to the preceding years [15]. Nevertheless, asthma prevalence rates in the 
United States and elsewhere have overall risen significantly over the past two decades. 
One of the challenges in ascertaining asthma prevalence is the issues around 
asthma and wheezing. A landmark asthma prevalence study in Arizona looked at the 
relationship between wheezing and asthma in children. The Tucson Children's 
Respiratory Study followed 826 children in their first six years and found that 490/o had 
problems with wheezing [16]. However, only 14% of those children had persistent 
wheezing and may be predisposed to asthma in later years. Another large study looked at 
older children in Australia In studying 8 to 11 year olds, Salome and colleagues, found 
that 34% had "any respiratory symptom," 24% were found to wheeze, 18% had airway 
hyperresponsiveness on pulmonary function testing, and only 13% were felt to have 
asthma [17]. Thus, while wheezing and pulmonary function testing are very important in 
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assisting with the diagnosis of asthma, the actual physician diagnostic rates are less and 
based on a combination of reasons. In conclusion, asthma prevalence has increased 
substantially over the past twenty years and improvements in diagnostic methods are of 
particular relevance in this disease. 
1.4 Epidemiology of Asthma: Major Risk Factors 
There are a number of well-described risk factors for higher asthma prevalence. 
Among the most common are ethnicity, socioeconomic status, environmental exposures, 
and respiratory infections. 
Although controversial, there is an increased risk for asthma in some ethnic 
groups. In the United States, the lifetime prevalence of asthma in children is clearly 
higher in the black population (12.5%) compared to the general Hispanic (7.1 %) or white 
population (7.5%) [18] The same 2004 Centers for Disease Control survey showed a 
rather low overall prevalence of adult asthma of 4. 7% in Hispanics but relatively similar 
prevalence rates in adult blacks (8.1%) and whites (7.4%). It must be noted that some of 
the ethnic risk factor component may be related to environmental exposures and 
socioeconomic access to health services and thus great care must be taken when 
determining any attributable risk on a racial basis [19]. Nevertheless, a recent study from 
Alberta, a jurisdiction with universal access to health care, shows that even after 
adjusting for socioeconomic status, there is still an increased risk for asthma in certain 
groups [20]. Studies in asthmatic children and women of same socioeconomic class but 
11 
different ethnic origin do show some physiologic differences and thus race appears to 
have at least some component of increased risk for asthma [21, 22]. 
Asthma has been definitively linked with low socioeconomic status. A survey of 
randomly selected children from Los Angeles in 2000 revealed asthma rates were highest 
in black children and children from low income groups [23]. In Canada, similar studies 
have shown linkage to low income groups. An elegant study from Saskatoon, 
Saskatchewan in 2006 by Muhajarine, showed a clear link between hospitalizations in 
children and other child health outcomes with the parent's socioeconomic status and the 
social context in which the child lives [24]. How much of the increased asthma 
prevalence is related to low income and what is the component of asthma risk from sub-
standard housing, air quality/pollution, ability to afford asthma medications, and other 
factors is not clear [25, 26]. 
Besides ethnic and income risk factors for asthma, environmental exposures are a 
significant risk for increased asthma prevalence. There appears to be a clear link between 
parental tobacco smoking and the risk of childhood asthma [27]. In addition, second-hand 
smoke exposure in non-smoking asthmatic adults has been shown in a prospective cohort 
study to increase asthma severity [28]. The National Health and Nutrition Examination 
Survey III in 1994 evaluated 18,825 adults and showed an overall prevalence of asthma 
of 4.5% and an increased prevalence rate related to current or past smoking and pet 
ownership [29]. Besides tobacco smoke exposure and pet exposure, other environmental 
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exposures are risk factors for asthma include house mites, cockroach allergen, and 
rat/mouse exposures (30]. 
Finally, another area being evaluated as an asthma risk factor is that of respiratory 
infections and allergen exposures. There is a clear increased prevalence of asthma among 
the developed world (31 ). Part of this increased prevalence may be on the basis of 
national reporting systems and strong surveillance programs in Western nations. 
However, other factors are involved. There is interesting evidence that improvements in 
hygiene can reduce the number ofT- 1 helper lymphocytes and increase the number ofT-
2 helper lymphocytes which related to atopy and allergy. This so-called hygiene 
hypothesis was first suggested by Strachan (32) and proposes that individuals in less 
hygienic environments will be exposed to allergens at a young age and thus maturing T -1 
helper lymphocytes rather than T-2 helper lymphocytes. The predominance ofT-1 helper 
lymphocytes in those populations is felt to lead to less allergies and asthma but follow-up 
studies have had variable results (33]. It should be noted that there is some difficulty with 
the hygiene hypothesis due to potential contribution of asthma risk from ethnic and 
socioeconomic differences. 
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1.5 Epidemioloc of Asthma: Economic Costs 
Asthma has a substantial economic burden both on the individual patient and 
society at large. For the patient, the costs of typical puffer medications in Canada can 
range from $25 to $200 per month depending on asthma severity. In the United States, it 
is believed that patients spend an average of $1 000 per annum on asthma medications 
[34). For society as a whole, there are significant problems due to absenteeism and/or 
decreased productivity. A recent study from France looked at the association between 
asthma control in children and the loss of workdays by their caregivers. They found that 
over a 1 year period 13% of parents missed over a week of work because of their child's 
symptoms [35). In Canada, the most detailed study evaluating the total health-care costs 
including hospitalizations, showed that Canadian asthma expenses were between $504 
and $648 million/year in 1990 [36). Thus, asthma is a very important disease from both 
the number of people affected and the total economic costs associated with it. 
1.6 Pathophysioloc of Asthma: 
The pathophysiology of asthma is related to three major factors including 
inflammation/edema of the bronchial walls, mucus production, and airway smooth 
muscle contraction and hypertrophy. Inflammation of the airways occurs with an initial 
trigger causing the release of inflammatory mediators from mast cell and macrophages. 
The trigger often is a specific agent such as cat dander or ragweed pollen, but may be a 
non-specific trigger that can be difficult to isolate and avoid. Mucus production is 
produced both by the initial inflammatory response but also later migration and activation 
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of eosinophils and neutrophils. Histologic studies show mucus gland and goblet cell 
hyperplasia There is also development of hypertrophy of the airway smooth muscle cells. 
Finally, individuals with asthma have an exaggerated bronchoconstrictor response to 
many triggers/agents. It is felt that airway inflammation is a key factor underlying the 
airway hyper-responsiveness which is one ofthe main hallmarks of asthma [37, 38]. 
1. 7 Diagnosis of Asthma: 
Clinical: 
Clinical history and physical exam are important in making the diagnosis of 
asthma In addition, this helps with the exclusion of asthma mimics, assessment of the 
severity of airflow obstruction, and the identification of risk factors and triggers. Classic 
asthma symptoms include episodic cough (dry or productive), wheezing, shortness of 
breath, and chest tightness. On physical examination, the physician often will find, by 
percussion of the chest, hyperinflated lungs and hear wheezes with a prolonged 
expiratory phase of respiration. 
Laboratory: 
Laboratory testing for asthma includes tests for atopy such as an eosinophil count 
or IgE level. Unfortunately, these tests are not specific for asthma. There are tests for the 
indirect assessment of allergic bronchial sensitivity such as allergy skin tests. However, it 
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is a minority of asthma patients who will clearly demonstrate a significant positive skin 
test. 
Pulmonary Function Testine;: 
Finally, there are the pulmonary function tests {PFT) that help with making a 
diagnosis of asthma and do clearly define the degree of airflow obstruction and airway 
hyper-responsiveness. Basic spirometry was first described by Hutchinson in 1846 with 
the invention of the water-seal spirometer. He used an inverted glass bell held by a pulley 
in a column of water. As the subject exhaled through a tube into the glass bell, the bell 
would move up as air displaced water. This allowed for measurement of vital capacity 
(VC) and forced vital capacity (FVC) which are measures of how much one can blow out 
from the lungs. Hutchinson reported measurements on 2130 patients and found that VC 
was directly related to height and inversely related to age. [39]. A water-seal spirometer 
when coupled to a fixed speed rotating kymograph would allow for the display of a 
volume (of exhaled air) over time (in seconds) graph. 
Spirometry was later refined by the concept of the timed vital capacity. This was 
described in French by Tiffeneau [ 40] in 1949 and in the English literature by Gaensler in 
1951 [ 41 ]. This concept of a timed vital capacity later became known as forced 
expiratory volume at one second (FEV 1 ). The inverted bell water displacement 
spirometry was brought into use in major medical centres in the 1940s and 1950s but was 
very heavy and not portable. In the 1960s, a new spirometer was developed based on dry 
displacement bellows allowing for more portability and office-based use. Finally, in the 
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1980s, pneumotachometers, electronic flow transducers, and computer circuits allowed 
for the development of hand-held spiro meters that would record flow-volume loops in 
addition to volume-time curves. 
The development of spirometry allowed researchers to accurately measure the 
amount of air in a subject's lungs and how fast that person could exhale the air. However, 
it is obvious that normative values are essential since a tall person will have larger lungs 
(and exhaled air) than a small person. Numerous spirometry studies have assessed the 
normal values for FEVl, FVC, and other lung measurements. It has been clearly 
demonstrated that there are differences based upon one's age, height, weight, gender, and 
ethnic origin. As one ages, there is a reduction in lung elasticity and function and thus 
predicted normal value FEVl declines with age. Increased weight also will affect PFT 
values. In regards to gender, it has been shown that women have slightly smaller chest 
volume than men of the same age, height, weight, and ethnic origin. The etiology of the 
ethnic differences are unclear but are likely related to the three-dimensional shape, size of 
lung, and the trunk/height ratio. 
Previous investigators have established normal values and developed prediction 
formula for FEV 1 and FVC values in the different groups based on age, height, weight, 
gender, and ethnicity. Generally, the predictive formulae are based upon non-smoking 
normal individuals although large-scale data from other research studies is available on 
smokers as well [42]. The major respiratory medicine associations have released position 
papers on the variation in the normal population, reference values, and the 
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standardization oflung function testing [43, 44, 45]. In addition to the normative values 
in the general population, there has been research into the improvement in airflow rates 
following inhaled bronchodilators. The American Thoracic Society (A TS) has developed 
criteria which suggest a significant post-bronchodilator FEV I response to be 200 
milliliters (ml) and 12% improvement from baseline [43]. Although other groups have 
suggested slightly different criteria, the generally accepted world-wide standards are the 
ATS criteria [46]. 
While FEVI has been used most frequently to help define asthma severity, the 
correlation between FEVI and asthma symptoms is not optimal [47]. Likely more 
important than the actual FEV1 is the degree of airway reactivity and a rapidly changing 
FEVI [48]. Because of this issue, it is common to use bronchoprovocation testing to 
assist with the diagnosis of asthma in atypical cases. It is well known that all individuals 
will have bronchoconstriction of their airways in response to various inhaled irritants. 
Patients with asthma tend to have an excessive response and thus bronchoprovocation 
testing may help identify hyperreactive airways. 
Histamine and methacholine are the two most commonly used agents for 
bronchoprovocation testing in North America. Methacholine is used predominantly 
because it has less systemic side effects. The method for methacholine/histamine testing 
involves a pre-test baseline spirometry, followed by nebulized inhalation of a small dose 
of the irritating agent, followed by repeat spirometry. This procedure is repeated using 
higher doses until either there is a 20% drop in FEV 1 or the patient reaches the maximal 
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dose. There are specific protocols for testing and interpretation that have been developed 
by the ATS [49]. In the atypical or difficult-to-diagnosis patient, either 
bronchoprovocation testing or bronchodilator responsiveness on spirometry can be very 
helpful towards eventual diagnosis of asthma Indeed. in one study of chronic dyspnea, 
almost 300/o of patients required these ancillary tests to achieve an asthma diagnosis [50]. 
However, it must be noted that while bronchoprovocation testing is highly sensitive for 
current asthma symptoms, the positive predictive value for is poor [51]. This is because 
other conditions (e.g. recent bronchitis, pneumonia, etc.) may also give a positive 
bronchoprovocation test. Thus, bronchoprovocation testing is not recommended as a 
general screening tool for asthma in the overall population and clinical history and 
correlation is needed. 
1.8 Summary: 
The current standard for asthma diagnosis is based on the typical clinical features 
in conjunction with a significant change in FEVI after bronchodilator administration. 
The level of bronchodilator response considered to be diagnostically significant has been 
the subject of controversy. Definition of the degree of airway reversibility varies widely 
[52, 53). The American Thoracic Society (A TS) has developed criteria which suggest a 
significant post-bronchodilator FEVl response to be 200 milliliters (ml) and 12% 
improvement from baseline [43]. To our knowledge, these criteria have never been fully 
validated in a North American population by testing against the clinical diagnosis of 
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asthma. In this study of patients seen at a tertiary care centre, who meet A TS spirometric 
criteria, we examine bronchodilator responses in reference to clinical diagnosis. 
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1.9 Research Question 
To evaluate the utility of the A TS post-bronchodilator criteria of airway 
hyperresponsiveness (12% improvement in FEVI and 200 cc volume) versus expert 
clinical diagnosis of asthma. 
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2.0 METHODS: 
2.1 Study Designs: 
This was a single site, Royal University Hospital (RUH), University of 
Saskatchewan, retrospective study of clinical medical records and pulmonary function 
laboratory data. 
2.2 Study population: 
The province of Saskatchewan has a population of approximately I million 
people. This includes 14.8% at 65 or more years of age, and 25% at less than 20 years of 
age (2003 data). This population enjoys universal health insurance. The provincial 
population is a diverse mix of ethnic backgrounds, with relatively large proportions of 
first nations and Caucasian peoples. There are eight hospitals for complete pulmonary 
function testing located in the province. 
Royal University Hospital tends to see patients from northern and central 
Saskatchewan and has a referral base in excess of 500,000 people. The RUH-based 
respirologists are the largest respiratory medicine group in the province with 10 of the 17 
adult respiratory medicine physicians in Saskatchewan. The RUH PFT laboratory does 
approximately 3500 different pulmonary function studies per year [personal 
communication with Dr. T Hurst, RUH PFT lab director]. The population examined in 
this study consisted of patients referred for PFT's for various lung diseases and 
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symptoms and subsequently seen in the outpatient respiratory medicine clinic at Royal 
University Hospital. 
2.3 Selection Process: 
All spirometry tests done on patients referred to the Royal University Hospital 
adult pulmonary function laboratory from September 1999 to September 2004 were 
reviewed. A total of 15,385 spirometry tests were performed during this period. All 
pulmonary function testing was performed in accordance with standard A TS protocol 
with the patient seated, the use of nose clips, and the best of three spirometry flow 
readings recorded. Vmax model 22 PFT machines (SensorMedics Yorba Linda, 
California) were employed. A significant bronchodilator response was defined per A TS 
criteria as an increase in FEV 1 of 200 m1 and 12% and/or an increase in forced vital 
capacity (FVC) of200 m1 and 12% [43]. There were a total of 1862 (12.1 %) tests 
meeting the FEV1 improvement criteria and 1916 (12.4%) tests meeting the FVC 
improvement criteria. A total of 644 individual patients were represented. When a 
patient had multiple spirometric tests, the most recent test results were recorded. As 
access to medical records was required for clinical correlation, only adult (age> 18) 
patients who had been seen in outpatient clinics by staff respirologists (n = 1 0) were 
included in this study. This comprised 310 ofthe 644 patients meeting ATS spirometric 
criteria for asthma. 
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2.4 Data Colledion: 
All medical records were reviewed by a single investigator employing a standard 
data collection form. Data collected included age, gender, height, weight, and clinical 
diagnosis (which included: asthma, copd, bronchiectasis, interstitial pulmonary fibrosis, 
bronchiolitis obliterans organizing pneumonia, pleural disease, non-specific cough, non-
specific dyspnea, cardiac disease, sinus disease, vasculitis, and obstructive sleep apnea). 
Also collected was the PFT data including pre- and post-bronchodilator FEVI, FVC, and 
MMFR (FEF 25-75). For the purposes of this study, all patients who had either an 
isolated diagnosis of asthma or a concomitant diagnosis of asthma were considered to 
have asthma for data analysis. The standard for asthma diagnosis was the staff 
respirologist's recorded diagnosis based on an extensive consultation assessment (history, 
complete physical examination, and spirometry) in the outpatient respirology clinic. A 
standard questionnaire was not used by the I 0 respirologists as this study was a 
retrospective real-life comparison of physician diagnosis in respect to ATS spirometry 
criteria. All ten staffrespirologists consented to the review of their patient' s data. 
2.5 Sample Size: 
The minimum sample size for this study was based on the primary research 
question of the utility of spirometric variables, A TS post-bronchodilator criteria of airway 
hyperresponsiveness (12% improvement in FEVt and 200 cc volume), in the diagnosis of 
asthmatic patients compared to other patients referred for PFTs. 
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As the primary outcome measure data is continuous in nature, the following 
equation was employed to calculate the minimum number of patients required in each 
group [54]: 
Where m = minimum patient number/group. 
where: Z1-a12 = 2.58, Z1_1l = 1.28, for a two sided a = 0.01, and a J3 = 0.1, d = o/o, and o is 
4.0% the percentage change in FEV1 post-bronchodilator standard deviation value [55]. 
The o is the value of the clinically significant difference in the post-bronchodilator FEV I. 
This has been set at 12% as this represents current A TS criteria for a significant post-
bronchodilator response. Equal sized groups were assumed. 
m = 2(2.58 + 1.28i + (2.58i 
(1214i 4 
m = a minimum of 5 patients per group were required for an a of 0.01 and 90% power ( l -
J3). 
2. 7 Statistical Analysis: 
SPSS v.l2.0 was employed for data entry and analysis. For the purpose of 
comparison, patients were divided into the categories of"asthma" and "not-asthma". The 
non-asthma group was further divided into "COPD", "bronchiectasis" and "other". The 
reason the non-asthma group was further subdivided was to try to isolate the "COPD" 
group in particular. Since COPD is a fairly common obstructive airflow disease in older 
individuals and some of these patients may have a partial reactive component, there is 
some clinical confusion at times between COPD and asthma The remainder of the non-
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asthma group is split between "bronchiectasis", a disease which often has reactive 
airways, and the "other" group. Two group comparisons of continuous data were 
performed using independent two-tailed t-tests. ANOVA was used for three or more 
group comparisons. The Bonferroni correction for multiple comparisons was utilized 
[56]. Frequency data was evaluated by chi-square testing. Comparison of varying levels 
of FEY l and FVC response between diagnostic groups allowed us to plot a receiver-
operator characteristic (ROC) curve [see Appendix C], which was used to further assess 
the value of these diagnostic criteria. 
Data was entered into a computer spreadsheet. Continuous or numerical data 
were entered directly, categorical data was given a numerical code i.e. for gender, male 
was coded as 1, female was coded as 2. The numerical code was entered into the 
spreadsheet for categorical or frequency data SPSS version 12.0 statistical software was 
utilized for data analysis. 
Continuous data was available for the following variables: age on a ratio scale, 
FEVl, FVC, MMFR, percentage change in FEVl , FVC, MMFR post-bronchodilator on 
an interval scale. Continuous data when normally distributed permit use of parametric 
analytic techniques. Characteristics of the data were assessed; including measures of 
central tendency, dispersion, skewedness and kurtosis. Comparisons were primarily 
between two groups. This allowed use oft-tests for two group comparisons. 
Independent 2-tailed t-tests were used for comparisons of continuous ratio/interval data 
between groups Two-tailed tests were used rather than one-tailed in order to assess 
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differences between the two groups in either a positive or negative direction. When 
appropriate, 95% confidence intervals were reported. In order to correct for multiple 
testing and avoid an increased risk of type I error, the alpha value required before 
rejection of the null hypothesis was divided by k (the number of comparisons made). 
Frequency data (categorical, binomial, or count data) was generated for gender 
and disease category. The chi-square distribution, which was used in this study is the 
most commonly utilized statistical method for analysis of frequency data [57]. However, 
the chi-square test is not an appropriate method of analysis if minimum expected 
frequency requirements are not met or if one of the expected frequencies is less than five. 
Accordingly, Fisher's exact test was used when one or more cell entries were less than 
five [57]. Multiple testing correction of a/k were also performed. 
In development of a predictive model, binary-logistic regression was utilized with 
the dichotomous outcome of asthma or non-asthma. Variables were included by 
'stepwise-enter' method. Variables were selected based on demonstrated association 
(p<O.Ol) with outcome in bivariate analysis. The Hosmer-Lemeshow goodness of fit test 
was employed [58]. Models were developed for the total population and separately for 
gender subgroups. 
2. 7 Ethical/ Administrative Approvals: 
Approval for this study was obtained from the University of Saskatchewan 
Research Ethics Board, and the Saskatoon District Health Research Services Unit. 
27 
3.0 RESULTS: 
3.1 Characteristics of the Study Population: 
Ofthe 310 adult respiratory clinic patients included in this study, 168 (54.2%) 
were male, and the remaining 142, female. The mean age ofthis population was 63.2 
years (range: 22-89). 
The clinical diagnoses represented in this population as extracted from the 
respiratory clinic medical record, were divided into four general categories: asthma, 
COPD, bronchiectasis, and 'other' (Figure 3.1.1.). The 'other' category included 
interstitial pulmonary fibrosis, obstructive sleep apnea, non-specific cough, non-specific 
dyspnea, pleural disease, sinus disorders, cardiac disease, vasculitis, and bronchiolitis 
obliterans organizing pneumonia The representation of these diagnostic categories 
within the population is outlined in Table 3.1.1. Asthmatics made up the majority with 
169/310 patients (54.5%). 
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Table 3.1.1.: Diagnostic category characteristics in study population 
Diagnosis Number of Body Mass Age* (years) %male 
patients Index• (kglm2) 
Asthma 169 (54.5%) 30.32 (7.48) 60.6 (7.5) 56.2% 
(95/169) 
COPO 85 (27.4%) 27.16 (5.78) 67.7 (11.5) 51.8% 
(44/85) 
Bronchiectasis 13 (4.2%) 26.10 (5.37) 55.7 (19.2) 61.5% 
(8/13) 
'Other' 43 (13.<)0/o) 29.95 (5.85) 66.7 (13.4) 48.8% 
(21143) 
310 (100%) 
Total: 
. . 
*Mean values prOVIded, standard deviations 1n brackets 
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Figure 3.1.1.: Diagnostic distribution of patient population 
four diagnostic 
categories 
• asthma 
II copd 
0 bronchiectasis 
• other 
In the population as a whole, the mean FEVI was 1.57liters (L), with a median of 
1.46 Land a standard deviation of0.67 (range 0.49 to 3.99). The FVC was 2.91 L with a 
median of2.78 Land a SD of0.93 (range 1.35 to 6.15). The FEF 25-75% was 0.75 
Lisee, with a median of0.56 Usee and a SD of0.58 (range 0.13 to 3.12). The mean 
percent improvement in FEV 1 post-bronchodilator for the total population was 18.66% 
(SD 6.35, median 16.67). The mean percentage improvement for FVC post-
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bronchodilator was 13.25% (SO 8.00, median 12.03). The mean percentage 
improvement in FEF 25-75% post-bronchodilator was 28.42 (SO 25.51 , median 25.53). 
The mean values for these variables in each of the diagnostic categories are outlined in 
Table 3.1.2 .. 
Table 3.1.2.: Percentage improvement in spirometry post-bronchodilator by diagnosis 
Variable Diagnosis Nwnber Mean 95% confidence 
of patients (standard deviation) intervals 
Percentage Asthma 169 14.02 (8.09) 12.79, 15.24 
improvement in COPD 85 13.65 (8.59) 11.80, 15.50 
FVC Bronchiectasis 13 10.75 (6.96) 6.55, 14.95 
'Other' 43 10.22 (5.84) 8.42, 12.02 
Total 310 13.25 (8.00) 12.36, 14.15 
Percentage Asthma 169 19.41 (6.89) 18.36, 20.45 
improvement in COPD 85 18.06 (5.59) 16.85, 19.27 
FEV1 Bronchiectasis 13 18.58 (5.66) 15.15, 22.00 
'Other' 43 16.91 (5.42) 15.24, 18.58 
Total 310 18.66 (6.35) 17.95, 19.37 
Percentage Asthma 169 29.28 (25 .27) 25.45, 33.12 
improvement in COPD 85 17.12 (19.88) 12.84, 21.41 
FEF 25-75% Bronchiectasis 13 39.79 (26.28) 23.91, 55.68 
'Other' 43 43.93 (26.45) 35. 79, 52.07 
Total 3 )0 28.42 (25.51) 25.57, 31.27 
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3.2 Comparison of PFT parameters between diagnostic groups. 
Comparison of percentage improvement in these variables between these four 
diagnostic categories revealed significant differences between groups. For percentage 
improvement in FEV 1 no significant differences were observed between the four 
diagnostic groups by ANOV A. For percentage improvement in FVC, differences were 
observed between the asthmatic group and the 'other' group (p = 0.035). No significant 
differences in FVC were observed between the asthmatic group in comparison to the 
COPD or bronchiectasis groups. Comparison of percentage improvement in FEF 25-75% 
revealed significant differences between the asthmatic group and both the COPD and 
'other' groups (p = 0.002, p = 0.004). Mean plots are illustrated in Figure 3.2.1. 
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Figure 3.2.1a. 
Mean percentage improvement in FVC post-bronchodilator in diagnostic groups 
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Figure 3.2.1 b. 
Mean percentage improvement in FEVl post-bronchodilator in diagnostic groups 
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Figure 3.2.1 c. 
Mean percentage improvement in FEF 25-75% post-bronchodilator in diagnostic groups 
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When the non-asthmatic diagnostic categories are collapsed into a single disease 
category the following is observed: a mean percentage FEVI improvement post-
bronchodilator of 17.82% (SD 5.51), mean percentage FVC improvement of 12.34% (SO 
7.86), mean percentage FEF 25-75% improvement of27.53% (SO 25.89). When these 
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values are compared to the asthma diagnostic group results, there is a difference between 
the percentage change in FEV I (p = 0.03I ). However, this finding loses significance 
when corrected for multiple comparisons. No significant differences were observed 
between percentage changes in FVC or FEF 25-75% between these two groups. The 
population was then divided into those in whom both the FEVI and the FVC criteria are 
met and those in whom just one of the two criteria are fulfilled. This comparison resulted 
in essentially equal numbers of patients in both the asthma and 'non-asthma' categories 
who met only one of the two A TS criteria. In the patients meeting both A TS criteria, 
93/I55 (60%) were diagnosed with asthma. This difference approached, but did not 
achieve significance with p = 0.06. 
The diagnostic role of magnitude of bronchodilator response was then considered. 
Ofthe 3IO patients meeting the I2% ATS criteria, I69 (54.5%) were clinically diagnosed 
with asthma. By increasing the requirement to I5% improvement in FEV I, there were 
II9/206 (57.8%) diagnosed with asthma. Of the 96 patients meeting a 200/o FEVI 
improvement, there were 61 (63.5%) with diagnoses of asthma. When requiring a 
percentage increase of 12% or greater in FVC and 15% or greater in FEV1 , there were 74 
asthmatics (60.2%) out of 123 patients. Within the confines of these arbitrary thresholds 
is apparent the highest positive predictive value at the 20% improvement in FEVI level. 
However, in this study population alone, all of whom met the A TS criteria for a I2 % 
improvement post-bronchodilator, altering the diagnostic cut-off point to 20%, results in 
a positive predictive value of63.5%, a negative predictive value of 49.5%, a sensitivity of 
36.1% and specificity of75.2%. 
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A receiver operator characteristic curve (Figure 3.2.2) was then utilized to further 
evaluate the relationship between diagnostic sensitivity and specificity of the A TS criteria 
within this particular study population. Recalling that when a test contributes no 
diagnostic information the area under the curve would equal 0.5, and when a test has 
100% sensitivity and specificity the area would then equal 1.0, values were obtained for 
area under the curve for percentage change ofFEV1 of0.569 (p = 0.037), ofFVC equal 
to 0.569 (p = 0.036), and of FEF 25-75% of 0.517 (p = 0.608). As visualized in Figure 
3.2.2, the ROC curve for each of these variables shadow the diagonal reference line. 
Fi20re 3.2.2.: Receiver Operator Characteristic curve 
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3.3 Examination of Characteristics of Gender Subpopulations: 
Dividing the population along gender lines, as in Table 3.3.1. the pulmonary 
function parameters for the total male and total female population are apparent. A 
comparison of the asthmatic subgroup with the non-asthmatic composite group is made 
for each gender in Tables 3.3.2. and 3.3.3 .. 
Table 3.3.1.: Comparison of PFT parameters between gender groups. 
Parameter Male n = 168 Female n = 142 
% asthmatics 56.5% (95/168) 52. I% (74/ I 42) 
Mean age (years) 63.62 (14.26) 62.70 (15.27) 
Baseline FEY I : 1.76 (0.70) 1.34 (0.562) 
Baseline FVC 3.34 (0.86) 2.40 (0. 722) 
Baseline FEF 25-75% 0.803 (0.6 I) 0.690 (.532) 
Percentage improvement in 18.88 (6.52) 18.39(6.16) 
FEV1 post-bronchodilator 
Percentage improvement in 13.65 (7.96) 12.78 (8.05) 
FVC post- bronchodilator 
Percentage improvement in 27.36 (23.44) 29.67 (27.80) 
FEF 25-75% post-
bronchodilator 
Body Mass Index kglm' 29.22 (5.79) 29.22 (8.04) 
. . Standard devulhons m br-ackets unless otherwise indiaud 
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Table 3.3.2.: Comparison of PFT parameters between asthmatic and non-asthmatic male 
patients 
Parameter Diagnostic group: mean value (SD) Significance level 95% confidence 
non-asthmatics n =73 intervals 
asthmatics n = 95 
Baseline FEV I Non-asthmatic 1.65 (0.658) p - 0.074 (-0.410, 0.020) 
Asthmatic 1.84 (0. 728) 
Baseline FVC Non-asthmatic 3.13 (0. 742) p - 0.004• ( -0.625, -0.120) 
Asthmatic 3.50 (0.916) 
Baseline FEF 25- Non-asthmatic 0. 796 (0.623) p = 0.889 ( -0.200, 0.174) 
75% Asthmatic 0.809 (0.598) 
% improvement in Non-asthmatic 17.80 (6.139) p = 0.058 (-3.915, 0.063) 
FEVI post- Asthmatic 19.72 (6.717) 
bronchodilator 
% improvement in Non-asthmatic 13.03 (8.238) p = 0.373 (-3.556, 1.342) 
FVC post- Asthmatic 14.13 (7.756) 
bronchodilator 
% improvement in Non-asthmatic 22.92 (2.682) p = 0.407 (-I 0249,4. I 72) 
FEF 25-7Wo post- Asthmatic 23.87 (2.449) 
bronchodilator 
• s1gn1ficant after correction for mult1ple compansons 
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Table 3.3.3.: Comparison of PFT parameters between asthmatic and non-asthmatic 
female patients. 
Parameter Diagnostic group: Mean value (SD) Significance level 95% confidence 
non-asthmatic n = 68 intervals 
asthmatics n = 74 
Baseline FEV I Non-asthmatic 1.16 (0.491) p < o.oot• ( -0.519, -0. 162) 
Asthmatic 1.50 (0.577) 
Baseline FVC Non-asthmatic 2.26 (0.656) p = 0.025 (-0.507, -0.034) 
Asthmatic 2.53 (0.761) 
Baseline FEF 25- Non-asthmatic 0.564 (0.482) p = 0.006• ( -0.416, -0.070) 
75% Asthmatic 0.807 (0.552) 
Percentage Non-asthmatic 17.72 (4.854) p = 0.208 (-3.296, 0.726) 
improvement in Asthmatic 19.00 (7.128) 
FEVI post 
bronchodilator 
Percentage Non-asthmatic 11 .595 (7 .360) p = 0.092 (-4.937, 0.376) 
improvement in FVC Asthmatic 13.876 (8.545) 
post-bronchodilator 
Percentage Non-asthmatic 29.26 (28. 730) p = 0.865 (-10.061 , 8.468) 
improvement in FEF Asthmatic 30.06 (27 . 108) 
25-75% post-
bronchodilator 
• stgmficant after correctton for multiple compansons 
3.4 Development of Diagnostic Predictive Models Utilizing Binary Logistic 
Regression: 
A binary logistic regression was then employed to develop a predictive model for 
asthma diagnosis. The binomial dependant variable was asthmatic or non-asthmatic. The 
40 
independent variables providing the best model were: percentage improvement in FEY I, 
baseline FEV1, age, height (metres), baseline FVC, percentage improvement in FVC 
post-bronchodilator, baseline FEF 25-75%, and percentage improvement in FEF 25-75% 
post-bronchodilator. These eight variables provide a model with a chi squared of 48.598 
with 8 degrees of freedom and p < 0.001. The Homer and Lemeshow goodness of fit test 
had p = 0.346. The classification table (Table 3.4.1) demonstrates 69.0% of predicted 
results to be correct. 
Table 3.4.1.: Logistic Regression Classification Table for Total Population. 
Predicted Diagnosis 
Non-asthmatic Asthmatic %Correct 
Observed Non-asthmatic 85 56 60.3 
Diagnosis Asthmatic 40 129 76.3 
Overall 69.0 
The Exp(B) for each variable is as follows: 
%improvement in FEV1 post-bronchodilator: Exp(B) = 1.054 (95% CI: 0.995, 
1.116), p = 0.076 
height: Exp(B) = 0.006 (95% CI: 0.000, 0.211 ), p = 0.005 
Baseline FEV1: Exp(B) = 20.813 (95% CI: 4.031, 107.462), p < 0.001 
age: Exp(B) = 0.990 (95% CI: 0.971, 1.010), p = 0.346 
baseline FVC: Exp(B) = 0.831 (95% CI: 0.412, 1.675), p = 0.604 
41 
%improvement in FVC post-bronchodilator: Exp(B) = 1.037 (95% CI: 0.992, 
1.085), p = 0.110 
baseline FEF 25-75%: Exp(B) = 0.128 (95% CI: 0.035, 0.463), p = 0.002 
%improvement in FEF 25-75% post-bronchodilator: Exp(B) = 0.989 (95% CI: 
0.976, 1.002), p = 0.103 
From this data it can reported that for this model from the total study population, 
the relative odds of a diagnosis of asthma increase by a factor of 1.054 for each unit 
increase in post-bronchodilator FEV1, increase by a factor of20.813 for each unit 
increase in baseline FEY 1, and increase by a factor of 1.037 for each unit increase in 
FVC post-bronchodilator. Conversely, the relative odds of a diagnosis of asthma 
decrease with a factor of0.986 for each year of age, with a factor of0.670 for each unit 
change in baseline FVC, decrease by a factor of0.114 for each unit change in baseline 
FEF 25-75%, and by a factor of0.992 for each percentage change in post-bronchodilator 
FEF 25-75.t 
Further evaluation of the predictive capacity of this model was performed 
utilizing a ROC curve (Figure 3.4.1.), employing the predictive model probability as the 
test variable. The area under the curve was calculated to be 0.723, with 95% CI of0.666 
and 0. 779 (p < 0.001 ). 
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Figure 3.4.1.: ROC curve for predictive model for total population 
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3.5. Development of Diagnostic Predictive Model in Female Subpopulation: 
The differences evident between the genders were sufficient that separate 
predictive models employing binary logistic regression were examined. Again employed 
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was the dichotomous outcome of asthmatic or non-asthmatic as the dependant variable in 
both gender models. The independent variables found to make the best model for women 
included percentage improvement in FEVI post-bronchodilator, baseline FEVI , age, 
baseline FVC, percentage improvement in FVC post-bronchodilator, baseline FEF 25-
75%, percentage improvement in FEF 25-75% post-bronchodilator, height (em), and 
weight (kg). These variables provide a model with a chi-squared of 44.953, with 9 
degrees of freedom and p < 0.00 1. The Homer and Lemeshow goodness of fit test had p 
= 0.486. The classification table {Table 3.5.1.) demonstrates 73.<)0/o of predicted results 
to be correct. 
Table 3.5.1.: Logistic Regression Classification Table for Female Population 
Predicted Diagnosis 
Non-asthmatic Asthmatic %Correct 
Observed Non-asthmatic 46 22 67.6 
Diagnosis Asthmatic 15 59 79.7 
Overall 73.9 
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The Exp(B) for each variable is as follows: 
%improvement in FEV1 post-bronchodilator: Exp(B) = 1.071 (95% Cl: 0.0964, 
1.190), p = 0.201 
Weight: Exp(B) = 1.022 (95% CI:0.997, 1.047 ), p = 0.080 
Height: Exp(B) = 0.906 (95% CI: 0.839, 0.978), p = 0.011 
Baseline FEV1 : Exp(B) = 262.027 (95% CI: 9.399, 7304.723 ), p = 0.001 
age: Exp(B) = 0.977 (95% CI: 0.944, 1.011), p = 0.176 
baseline FVC: Exp(B) = 0.260 (95% CI: 0.061, 1.107 ), p = 0.068 
%improvement in FVC post-bronchodilator: Exp(B) = 1.027 (95% CI: 0.960, 
1.100), p = 0.441 
baseline FEF 25-75%: Exp(B) = 0.070 (95% CI: 0.007, 0.689 ), p = 0.023 
%improvement in FEF 25-75% post-bronchodilator: Exp(B) = 0.981 (95% CI: 
0.962, 1.001 ), p = 0.061 
From these results employing data for the female study population, it can be said 
that within this predictive model, the relative odds of a diagnosis of asthma increase by a 
factor of 1.071 for each percentage unit increase in post-bronchodilator FEV1 , increase 
by a factor of 1.022 for each kg of weight, increase by a factor of 262.027 for each unit 
increase in baseline FEV 1, and increase by a factor of 1.027 for each percentage unit 
increase in post-bronchodilator FVC. Conversely, the relative odds of a diagnosis of 
asthma decrease with a factor of0.906 for each unit of height, decrease with a factor of 
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0. 977 for each year of age, decrease with a factor of 0.260 for each unit change in 
baseline FVC, decrease with a factor of0.070 for each unit change in baseline FEF 25-
75%, and decrease with a factor of0.981 for each percentage unit change in post-
bronchodilator FEF 25-75%. 
Further evaluation of the predictive capacity of this female subpopulation model 
was performed utilizing a ROC curve (Figure 3.5.1.), employing the predictive model 
probability as the test variable. The area under the curve was calculated to be 0.802, with 
95% CI of 0. 731 and 0.873 (p < 0.001 ). 
Figure 3.5.1.: ROC curve for predictive model in female subpopulation 
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3.6. Development of a predictive model for the male subpopulation: 
The independent variables found to make the best model for men included 
percentage improvement in FEV 1 post-bronchodilator, baseline FEV 1, age, baseline 
FVC, percentage improvement in FVC post-bronchodilator, baseline FEF 25-75%, 
percentage improvement in FEF 25-75% post-bronchodilator, and body mass index 
(BMI). These variables provide a model with a chi-squared of25.14, with 8 degrees of 
freedom and p = 0.001. The Homer and Lemeshow goodness of fit test had p = 0.927. 
The classification table (Table 3.6.1.) demonstrates 66.7% of predicted results to be 
correct. 
Table 3.6.1: Logistic Regression Classification Table for Male Population 
Predicted Diagnosis 
Non-asthmatic Asthmatic %Correct 
Observed Non-asthmatic 37 36 50.7 
Diagnosis Asthmatic 20 75 78.9 
Overall 66.7 
The Exp(B) for each variable is as follows: 
%improvement in FEVI post-bronchodilator: Exp(B) = 1.057 (95% Cl: 0.981 , 
1.139), p = 0.148 
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BMI: Exp(B) = 1.035 (95% Cl: 0.972, 1.102), p = 0.285 
Baseline FEV1: Exp(B) = 9.214 (95% CI 1.074, 79.053), p = 0.043 
age: Exp(B) = 1.003 (95% CI: 0.975, 1.032), p = 0.836 
baseline FVC: Exp(B) = 1.330 (95% CI: 0.546, 3.239), p = 0.531 
%improvement in FVC post-bronchodilator: Exp(B) = 1.032 (95% Cl: 0.968, 
1.099), p = 0.339 
baseline FEF 25-75%: Exp(B) = 0.111 (95% CI: 0.0 19, 0.653 ), p =0.0 15 
%improvement in FEF 25-75% post-bronchodilator: Exp(B) = 0.993 (95% 
CI:0.973, 1.013 ), p = 0.507. 
From these results employing the male study population, it can be said that within 
this predictive model the relative odds of a diagnosis of asthma increase by a factor of 
1.057 for each percentage change in post-bronchodilator FEVl, increase by a factor of 
1.035 for each unit change in BMI, increase by a factor of9.214 for each unit change in 
the baseline FEV I, increase by a factor of 1.003 for each year of age, increase by a factor 
of 1.33 for each unit change in the baseline FVC, and increase by a factor of 1.032 for 
each percentage change in post-bronchodilator FVC. Conversely, the relative odds of a 
diagnosis of asthma decrease with a factor of 0.111 for each unit change in baseline FEF 
25-75%, and decrease with a factor of 0.993 for each percentage change in post-
bronchodilator FEF 25-75%. 
Further evaluation of the predictive capacity of this male subp:>pulation model 
was performed utilizing a ROC curve (Figure 3 .6.1 ), employing the predictive model 
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probability as the test variable. The area under the curve was calculated to be 0.709, with 
95% CI of0.63l and 0.788 (p < 0.001 ). 
Figure 3.6.1.: ROC curve for predictive model in male subpopulation 
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4.0 Conclusions: 
1. No statistically significant difference in mean percentage improvement in FEV 1 post-
bronchodilator was observed between asthmatic patients and the non-asthmatic patients. 
2. Patients meeting both FEVl and FVC ATS criteria consisted of essentially equal 
numbers of asthmatics and non-asthmatics. 
3. Significant differences in baseline spirometric data were evident between male 
asthmatics versus non-asthmatics and also between female asthmatics versus non-
asthmatics. However, no persistence of significant post-bronchodilator changes were 
evident for either group. Thus, use of the A TS criteria for post -bronchodilator 
improvement is unhelpful in distinguishing asthma in this patient population. 
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5.0 Discussion: 
There has long been controversy regarding the definition of airway obstruction 
and significant bronchodilator response. The threshold at which the spirometric criteria 
are set determine the prevalence of airways obstruction in the general population. In a 
recent large cross-sectional study, Viegi et al showed clear differences between "clinical 
criteria" and both European Respiratory Society (ERS) and A TS definitions of airways 
obstruction [59]. In that population, the A TS criteria had the highest sensitivity but 
lowest specificity for any respiratory symptom or disease. Likewise, there is variation in 
the clinical assessment ofFEVl bronchodilator response. In a recent Australian survey 
of laboratory testing practices for bronchodilator reversibility testing, Borg found 
significant variation in methods used to assess and interpret bronchodilator response [60]. 
Even with careful and consistent application of a single method for assessing 
bronchodilator response, there can be variation over time in the percentage of FEY 1 
improvement [61]. In the ISOLDE study population of moderate to severe COPD 
patients, investigators found that bronchodilator responsiveness was a continuous 
variable and over 52% of patients changed responder status between tri-monthly 
physician visits [62]. Finally, the ATS criteria have been found to inappropriately 
classify a high percentage of patients with lower heights as having a non-reproducible 
test [63]. This further emphasizes the need to use spirometric criteria as a guide but not 
as an unimpeachable gold standard by which to make a diagnosis of asthma. 
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In this study population, relying on spirometric criteria alone was found to be 
inadequate in asthma diagnosis as only 54.7% of 311 patients meeting A TS 
bronchodilator response criteria were felt to be asthmatic clinically. By raising the 
threshold of FEV I bronchodilator response above the 12% required by A TS criteria, 
there was a little improvement in the positive predictive value of the spirometric test 
results, increasing from 54.5% to 63.5%. This increased positive predictive value was 
associated with a low sensitivity of 36.1 %. When the spirometry results of the asthmatic 
patients were compared with those from the COPD, bronchiectasis and 'other' disease 
categories, there were no significant differences between groups for percentage 
improvement in FEVI, and only between the asthma group and 'other' group for 
percentage improvement in FVC. 
The receiver operator characteristic areas under the curve values for these 
variables, although statistically significant, are uncomfortably close to the diagonal 
reference line which represents a test that contributes no information. These study results 
suggest the current A TS criteria are relatively non-specific for asthma Sensitivity of 
these current criteria was outside the scope of this study as only patients actually meeting 
the PFT criteria were included in this study. 
As this study population was drawn from a tertiary care hospital PFT laboratory 
and respirology subspecialty clinical practice, these findings may not be generalizable to 
other populations. Of note, the mean age of asthmatics in this study population was 
higher than asthmatics in the general population. Furthermore, the patient population 
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included in this study was heterogeneous with both new and longstanding respiratory 
clinic patients. Accordingly, varying degrees of phannacotherapeutic intervention would 
have been utilized. Clearly since the majority of follow-up clinic patients, who had been 
diagnosed with asthma, would be receiving appropriate medications, one may expect 
their spirometric data to reflect lesser baseline bronchoconstriction than new clinic 
patients. The goal in asthma therapy is to have normal or near normal lung function and 
symptom control. This anticipated superior control may result in a lesser degree of post-
bronchodilator improvement in established asthma patients, which would influence the 
results. Thus, it is quite possible that some asthmatics were excluded from this study as 
their most recent PFTs (on ideal asthma control therapy) would not meet the A TS 
criteria. However, it should be pointed out that the research patient population was 
selected to include only those who, at the time of clinical assessment, met A TS PFT 
criteria. Recognized and treated asthmatics who no longer met the 12% improvement 
post-bronchodilator requirement would not have been included for study. However, the 
purpose of this study was to evaluate the utility of the A TS post-bronchodilator criteria of 
airway hyperresponsiveness versus expert clinical diagnosis in the patient population 
meeting the A TS criteria. Nevertheless, it is possible that the asthma patient study sample 
is not representative of the asthma population in general. 
This study is limited in that it is a retrospective analysis comparing a recorded 
clinical diagnosis of asthma to spirometric results from the same date. Retrospective 
extraction of data from clinical records may be less rigorous than a prospective approach. 
The recorded clinical diagnoses had been arrived at by history and physical examination 
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of the patients by experienced respirologists at a single site. The spirometric data was 
usually available to these physicians at the time of the clinic visit and could potentially 
have influenced the clinical diagnosis. For example, in an unclear or borderline decision 
about asthma, a clinician may overly rely on spirometry or additional testing such as a 
bronchoprovocation test (e.g. methacholine challenge). Certainly in the comparison of 
spirometry with expert clinical diagnosis, the spirometry findings may affect the expert 
clinical diagnosis which is being used as the "gold standard." However, one would expect 
any bias to be in favour of a diagnosis of asthma given this research population who all 
met the A TS spirometry criteria for asthma. 
Another potential issue with this study is that of multiple observers. There were 
ten different respirologists contributing to this data pool. Interobserver variation in 
diagnosis was not determined, as patients had been seen by a single respirologist only. It 
has been previously recognized that significant variation can exist between respirologists 
both in the classification of obstruction as well as determination of bronchodilator 
response. In an Argentinean study of 30 respirologists, the degree of disagreement for 
response to bronchodilator was 24% [64]. Thus, while the ATS criteria are not the "gold 
standard" for asthma diagnosis, it must also be acknowledged that even expert clinicians, 
reviewing the same patient and PFT data, may disagree about asthma diagnosis. This 
further illustrates the importance of a comprehensive evaluation of all potential asthma 
patients along with their PFT data. Nevertheless, expert clinical assessment along with 
the less well-defmed "art of medicine", remains the standard for asthma diagnosis. 
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It is notable that many patients who did not have a clinical diagnosis of asthma 
had what is considered a significant bronchodilator response. In previous studies, it has 
been well recognized that approximately 10% of the COPD population has a component 
of bronchodilator response [65]. Also, a high percentage of patients with bronchiectasis 
have a bronchodilator response as previously shown as part of the clinical spectrum for 
that disease. However, there are other clinical findings that usually make the diagnosis of 
bronchiectasis fairly clear (e.g. significant purulent sputum, chest radiograph changes, 
etc). COPD can be more easily confused with asthma but also has certain classic findings 
that help to differentiate it. Overall, this study was to assess the usefulness in A TS 
bronchodilator criteria in the diagnosis of asthma. The findings that other diseases may 
have a significant bronchodilator response simply helps make the pure reliance on A TS 
criteria rather suspect and points to the importance of a comprehensive approach of 
history, physical examination, and PFT data analysis. 
In summary, while the ATS FEVI & FVC criteria are helpful in the diagnosis of 
asthma, relying on spirometric criteria alone is inadequate. In this study, only 54.7% of 
patients meeting the ATS bronchodilator improvement criteria were felt clinically to have 
asthma. Thus, use of the ATS criteria for post-bronchodilator improvement alone is 
unhelpful in distinguishing asthma in this patient population. The diagnosis of asthma 
depends upon a careful history, physical examination and consideration of 
complementary pulmonary function tests. Spirometric changes can be helpful in 
supporting the diagnosis, but the true significance of various levels of bronchodilator 
response remains unclear. 
55 
Appendix A: 
ATS Criteria for a Significant Post-bronchodilator Response in FEV1 (or FCV) 
A significant improvement is considered an increase in post-bronchodilator FEV 1 of 200 
milliliters and 12% improvement from baseline FEV 1. 
Reference: 
American Thoracic Society. Standardization of spirometry. 1994 update. Am J Respir 
Crit Care Med 1995;152:1107-36. 
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Appendix B: Data Collection Form 
Patient Study Number __ _ 
Age__ Gender Height__ Weight__ Calculated BMI 
Referring Physician ______ _ 
Consulting Respirologist ____ _ 
Date seen in clinic 
--------
Clinical Diagnosis _______ _ 
Date ofPFTs 
----
Baseline FEVl __ _ Baseline FVC __ _ Baseline FEF25-75 
---
Post-BD FEVl __ _ Post-BD FVC __ _ Post-BD FEF25-75 
---
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Appendix C: Discussion of the ROC curve 
ROC is an abbreviation for receiver operator characteristic. This terminology 
reflects the origins of this form of analysis. ROC methodology was first developed to 
help distinguish radar signals from background noise and was the principal graphic 
device for signal detection theory. The motivation for more accurate radar data arose 
from World War II, following the Pearl Harbor bombings, when the importance of being 
able to distinguish enemy aircraft became obvious (66]. 
Soon after the end of World War II, the ROC had been taken up and used in 
experimental psychology and psychophysics [ 67]. 
Leo Lusted, a radiologist, first broached the concept of using ROC analysis in the 
medical decision making process. In 1969 he began employing this technique in studies 
of medical imaging devices [68]. 
Eventually, ROC analysis became widely used in clinical medicine. It is 
generally utilized in evaluating the effectiveness of one therapy or diagnostic tool in 
comparison to a previously established one. This method is extensively employed in 
epidemiologic medical research. A current medical literature search employing the term 
' receiver operator characteristic curve' yields well over 1 000 entries today. 
ROC analysis is also used in the Social Sciences, where it is also known as ROC 
Accuracy Ratio. In this field it is a frequently employed method of evaluating accuracy 
of default probability models. ROC curves have also been increasingly employed in 
machine learning. In this setting Spackman first demonstrated the value of ROC curves 
in the comparison and evaluation of different classification algorithms [69]. 
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In clinical medicine, the process of making a diagnosis may involve a number of 
different forms of examination assessments, ranging from physical examination 
parameters, laboratory measurements from various bodily fluids or tissues, radiographic 
features or measurements, or as in this study, physiologic function parameter 
measurements. The diagnostician will need to choose a point at which the parameter 
being examined will be decided to have changed from normal to abnormal. The 
establishment of this "cut-point" permits the evaluation method to categorize the patient's 
test as either showing or not showing the presence of disease. By creating this threshold 
value, a continuous outcome measure has been changed into the dichotomy of being 
positive or negative for disease. 
Unfortunately, for the sake of simplicity, the 'cut-point' chosen inevitably will 
result in some 'normal' or disease-free patients having test results falling into the 
'positive' for disease range. Others who are 'abnormal' or known to be carrying the 
disease will have test results in the 'negative' range. These groups obviously represent 
the false positive and false negative fractions of the population tested when compared to 
an established standard of diagnosis (often referred to as the 'gold standard'). 
With this knowledge derived by comparison to the gold standard, sensitivity and 
specificity of the diagnostic test under examination may be computed. Recalling that 
sensitivity is a reflection of the true positive fraction (true positive/true positive+ false 
negative), and specificity a reflection of the true negative fraction (true negative/true 
negative+ false positive) in the population being tested. Modification of the diagnostic 
threshold point or 'cut-point' in either an upward or downward direction will influence 
the proportion of patients who would fall into the false positive and false negative groups. 
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Thereby, every degree of alteration of the 'cut-point' results in change in the sensitivity 
and specificity for the diagnostic test. For every such test employed by diagnosticians, a 
multitude of sets of sensitivities and specificities exist. The clinical scientist needs to be 
able to choose the most appropriate or optimal set for application towards the disease or 
disorder in question. The prevalence of the disease in the population being tested and the 
implications of the disease itself need to be considered. For example, in the case of a 
diagnosis of a treatable cancer a high sensitivity would be highly desirable, even at the 
cost of a low specificity with many false positive individuals who would then be able to 
be eliminated by a further more definitive test. On the other hand, giving medications to 
a child wrongly diagnosed as having attention-deficit hyperactivity disorder exposes that 
child to short and long term risk of adverse events and the stigma of a label, whereas 
missing the diagnosis may simply delay the intervention. In that scenario a lower 
sensitivity with a high specificity would be preferable. No one ideal, cut-point exists for 
all ROC curves. The diagnostician needs to weigh the benefits of high sensitivity with the 
potential risks of lower specificity and find an appropriate and acceptable middle ground 
for the specific disorder and population in question. 
The ROC curve itself is a two dimensional graphic plot of sensitivity (the true 
positive rate) on they axis versus !-specificity (the false positive rate) on the x axis. This 
visual representation demonstrates the spectrum of sensitivity and specificity across the 
range of possible 'cut-points'. Once the curve is constructed, it is possible to evaluate the 
diagnostic accuracy ofthe test by measuring the 'area under the (ROC) curve', also 
termed the 'c' statistic. The closer this area is to 0.5, the closer the morphology of the 
curve is to the diagonal and the less useful. The diagonal indicates the test is no better 
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than chance at discriminating between the presence and absence of disease. The diagonal 
therefore represents the null hypothesis. The more the ROC curve swings toward the 
upper left hand comer, the better the sensitivity and specificity of the test. An entirely 
perfect test would have an area of 1.0, with 1 000/o sensitivity and 1 000/o specificity. In 
this case the plotted line would run straight up the y axis until the top and then run 
horizontally. The existence of such a test is highly unlikely. However, the closer the 
area is to 1.0, the better the test is at distinguishing between affected and unaffected 
populations f70]. 
There are distinct advantages to employing ROC curves in clinical research. The 
visual presentation is easily appreciated and is highly complementary to sensitivity and 
specificity tabular data. It is a comprehensive representation of pure accuracy over the 
entire range of the test. The sensitivity and specificity for any chosen "cut-point" are 
readily available. The ROC curve is independent of prevalence, although prevalence of 
disease must be taken into account in choosing a 'cut-point'. In contrast to many analytic 
tools, it is not imperative to have normally distributed data. ROC curves can be used for 
both nonparametric and parametric data. In contrast to the smooth curve of the latter, the 
former has the disadvantage of a staircase appearance and can compare plots only at 
observed sensitivity and specificity. It is possible to calculate standard errors and go on 
to sample size estimation from ROC data [71]. 
Disadvantages of ROC plots include the absence of clearly identifiable features 
on the graph, including the decision thresholds and the number of subjects. Also, 
generally, construction of ROC plots requires utilization of computer software; however 
this is less of a concern with the 'user-friendly' resources which are now available. Other 
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concerns include background or random 'noise' or random variations which might affect 
the curve and degrade test performance. The largest issue appears to rest with the 
utilization of a gold standard for comparison. If the gold standard is not independent of 
the test under examination. the interdependence will give you a spuriously high area 
under the curve value. Additionally, if the test employed as the gold standard is poor at 
identifying disease. it is difficult to truly assess accuracy of any other form of 
discrimination whether by ROC curve or other method of comparison. Error can also 
arise from the presence of a co-morbidity which may influence the test. from verification 
bias on the part of the unblinded clinician, interobserver variation in situations where a 
subjective measurement is taken. 'test-review' bias. and 'incorporation' bias where the 
test result is incorporated into the evidence used to diagnose the disease. Finally, it 
should be recognized that tests are applied to specific populations and ROC curves reflect 
the sensitivity and specificity of the results in that specific patient population. 
Extrapolation to different populations may not be appropriate. For example. a test used to 
diagnose an advanced bulky malignancy may fail to diagnose or have a very low 
sensitivity for a small early form of the same disorder [721. 
A receiver operator characteristic plot can be most useful in comparison of two or 
more measures. A test with a curve that lies completely above the curve of another will 
be obviously superior in accuracy. ROC curves which cross require more extensive 
comparison analysis than those entirely separate [73). 
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